Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, ...

Concomitant systemic mastocytosis (SM) can complicate acute myeloid leukaemia (AML) with t(8;21) and its recognition, particularly in the presence of KIT D816 mutations, according ...

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial AdvancesHOUSTON, May 29, ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat ...

HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, ...

Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as ...

With the ease of online publishing, the number of journals has exploded, and with them the number of papers. It has gotten ...

Racura believes its reworked cancer-fighting and cardio-protective agent bisantrene will be a catalyst to push share prices ...